Filing Flows › Longeveron (LGVN) › Q1 2025
Longeveron (LGVN) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 8, 2025
Longeveron (LGVN) reported revenue of $381K for the first quarter 2025 (Q1 2025), -30% from a year earlier and -37% from the quarter before.
Longeveron, Q1 2025: revenue $381K (-30% year over year), net loss $5.0M, operating cash flow −$4.7M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $381K | -37% | -30% |
| Operating profit | −$5.2M | — | — |
| Net earnings | −$5.0M | — | — |
| Operating cash flow | −$4.7M | — | — |
What changed
Revenue was $381K in Q1 2025, down 30% year over year and down 37% from the previous quarter. Clinical Trial Revenue was the largest line at 68% of revenue. Clinical Trial Revenue lost $256K year over year (down 50%), 153% of the total change.
Gross margin was 72.2%, up 12.1 points from a year earlier. Operating costs exceeded revenue by $5.2M, an operating margin of -1359.8%. Operating expenses grew 23% against a revenue fall of 30%. The fastest-growing cost line was General & admin (+34%). The quarter ended with a net loss of $5.0M, wider than the previous quarter's $4.1M loss.
Operating cash flow was −$4.7M. Non-cash charges added back $421K of depreciation and amortization and $340K of share-based compensation. Working capital and other items used $447K. Capital expenditures of $27K exceeded it, leaving free cash flow of −$4.7M.
Questions
What was Longeveron's revenue in the first quarter 2025?
Longeveron (LGVN) reported revenue of $381K for the first quarter 2025 (Q1 2025), -30% from a year earlier and -37% from the quarter before.
Source: Longeveron 10-Q on SEC EDGAR.